Identifying human cancers to target with BCL-2 inhibition
Shifting the focus in lymphoma treatment
The importance of diagnosing DLBCL on a molecular level and how it will improve treatment
Combining radiotherapy and the immune system in lymphomas
Is venetoclax appropriate for relapsed CLL patients?